# A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

> **NCT06992687** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** HB0052 Injection

## Key facts

- **NCT ID:** NCT06992687
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06992687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06992687, "A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06992687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*